On the public citation graph

Clarithromycin for Early Anti-Inflammatory Responses in Community-Acquired Pneumonia: The ACCESS Randomized Trial

https://doi.org/10.2139/ssrn.4526511
0 signed · 22 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2009.1297openalex-extracted
Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections
inferredcites →https://doi.org/10.1001/jama.2016.0287openalex-extracted
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
inferredcites →https://doi.org/10.1016/j.chom.2020.04.009openalex-extracted
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
inferredcites →https://doi.org/10.1016/j.ijantimicag.2015.04.010openalex-extracted
Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/s1473-3099(16)00017-7openalex-extracted
Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)
inferredcites →https://doi.org/10.1056/nejmoa1800201openalex-extracted
Omadacycline for Community-Acquired Bacterial Pneumonia
inferredcites →https://doi.org/10.1093/cid/cis414openalex-extracted
Macrolide-Based Regimens and Mortality in Hospitalized Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis
inferredcites →https://doi.org/10.1093/cid/civ927openalex-extracted
Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health: Table 1.
inferredcites →https://doi.org/10.1093/cid/ciz090openalex-extracted
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
inferredcites →https://doi.org/10.1093/jac/dku033openalex-extracted
β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1097/ccm.0b013e3182a66b9bopenalex-extracted
Macrolides and Mortality in Critically Ill Patients With Community-Acquired Pneumonia
inferredcites →https://doi.org/10.1111/j.1469-0691.2012.03838.xopenalex-extracted
Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials
inferredcites →https://doi.org/10.1111/resp.12835openalex-extracted
Beta‐lactam plus macrolides or beta‐lactam alone for community‐acquired pneumonia: A systematic review and meta‐analysis
inferredcites →https://doi.org/10.1128/aac.05798-11openalex-extracted
Effect of Clarithromycin in Inflammatory Markers of Patients with Ventilator-Associated Pneumonia and Sepsis Caused by Gram-Negative Bacteria: Results from a Randomized Clinical Study
inferredcites →https://doi.org/10.1164/rccm.200512-1922ocopenalex-extracted
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
inferredcites →https://doi.org/10.1164/rccm.201908-1581stopenalex-extracted
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
inferredcites →https://doi.org/10.1164/rccm.202004-1201ocopenalex-extracted
Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial
inferredcites →https://doi.org/10.1164/rccm.202005-1583ocopenalex-extracted
Characterization of the Inflammatory Response to Severe COVID-19 Illness
inferredcites →https://doi.org/10.1179/joc.2010.22.4.264openalex-extracted
Clinical Efficacy of Moxifloxacin Versus Comparator Therapies for Community-Acquired Pneumonia Caused byLegionellaspp.
inferredcites →https://doi.org/10.1183/13993003.00735-2022openalex-extracted
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
inferredcites →https://doi.org/10.1186/s13054-022-04055-4openalex-extracted
Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial
inferredcites →https://doi.org/10.1378/chest.101.6.1644openalex-extracted
Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.